NRX Pharmaceuticals Inc. (NRXP) is an American biopharmaceutical company dedicated to the development of innovative medicines to treat underserved neurological disorders and life-threatening conditions. The company is committed to delivering effective treatment options that can improve the quality of life for patients and provide new hopes for complex cases.
NRX Pharmaceuticals was founded on the understanding that new, innovative treatments are needed for diseases that currently have inadequate therapies. Operating on the cutting-edge of drug discovery and development, the company's primary area of focus is on neurological disorders, including those that are life-threatening.
One of the leading candidates in its pipeline of treatment options is ZYESAMI™ (Aviptadil), a synthetic form of the human Vasoactive Intestinal Polypeptide (VIP) which has shown potential in treating critical Covid-19 in patients with respiratory failure. VIP is naturally produced in the lungs and has been shown in numerous studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation.
The company is also working on a non-opioid treatment for suicidal ideation and behavior, NRX-101. It received a Breakthrough Therapy Designation by the FDA for the treatment of severe bipolar depression in patients with Acute Suicidal Ideation and Behavior (ASIB) following an initial approval for a phase 2b/3 study.
NRXP operates under the leadership of a team of executives and scientists with a wealth of experience in the pharmaceutical and biotech industries. This includes Jonathan Javitt, MD, MPH, the company's CEO and Founder, who is a trained neurologist and ophthalmologist.
The company also stands committed to its corporate social responsibility, with a framework that ensures that its business practices support health, sustainability, and corporate citizenship. NRX Pharmaceuticals prioritizes a culture of accountability, ensuring they work responsibly and ethically in the interest of patients, employees, and the global community.
From its inception, NRX Pharmaceuticals Inc. has strived to make a significant difference in patients' lives. Whether it's through groundbreaking treatments for Covid-19 or novel therapies for mental health conditions, the company continues to be driven by the desire to address unmet medical needs, innovate healthcare solutions, and enhance patient outcomes.